Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3969 results

Sort By:

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Study ID: NCT06589830
Start Date: 2025-07
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

80

Intervention / Treatment

TL938 Capsules

Trastuzumab

Sponsor

Suzhou teligeene ltd.

Source: clinicaltrials.gov

Share:
Add to list

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure

Study ID: NCT06907667
Start Date: 2025-08
End Date: 2026-08
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

735

Intervention / Treatment

Vaccine injection

Sponsor

Nice University Hospital Center

Source: clinicaltrials.gov

Share:
Add to list

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Study ID: NCT06698744
Start Date: 2025-07
End Date: 2028-09
Study Type

Interventional

Study Phase

Phase1

No. of Participants

12

Intervention / Treatment

UF-KURE-BCMA CAR T-cells

Cyclophosphamide

Fludarabine

Sponsor

David Wald

Source: clinicaltrials.gov

Share:
Add to list

Study of Cognitive and Behavioural Biases in People With Idiopathic Environmental Intolerance (IEI) Versus Healthy Controls

Study ID: NCT06800976
Start Date: 2025-07
End Date: 2029-03
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

64

Intervention / Treatment
Sponsor

National Institute of Health and Medical Research, France

Source: clinicaltrials.gov

Share:
Add to list

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer

Study ID: NCT06524544
Start Date: 2025-08-01
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

384

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Pembrolizumab

Administration questionnaire

Sacituzumab Govitan

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Study ID: NCT06941376
Start Date: 2025-07
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Methotrexate (MTX)

AZthitrine (Don't)

Adalimumab

Infliximab

Tocilizumab

Sponsor

University of Pennsylvania

Source: clinicaltrials.gov

Share:
Add to list

Community Health Workers in an Interdisciplinary Outpatient CKD Clinic to Optimize Social Care Navigation, Patient Engagement, and Home Dialysis Utilization

Study ID: NCT06925776
Start Date: 2025-06-30
End Date: 2027-06-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

106

Intervention / Treatment

CHOOSE Home Intervention

Usual Care

Sponsor

Montefiore Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

Study ID: NCT06979076
Start Date: 2025-07
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

12

Intervention / Treatment

MS-553, DS1

MS-553, DS2

Sponsor

MingSight Pharmaceuticals, Inc

Source: clinicaltrials.gov

Share:
Add to list

The Disrupted Bodily Self of Patients

Study ID: NCT04957576
Start Date: 2027-01
End Date: 2029-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

5

Intervention / Treatment

Visuo-tactile stimulation

Sponsor

University of Geneva, Switzerland

Source: clinicaltrials.gov

Share:
Add to list

Psilocybin for Opioid Use Disorder (OUD)

Study ID: NCT06796062
Start Date: 2025-08
End Date: 2029-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

480

Intervention / Treatment

Psilocybin

Sponsor

NYU Langone Health

Source: clinicaltrials.gov

Share:
Add to list